Weight & Metabolic Health
What Happens When You Stop Taking a GLP-1 (And What Maintenance Actually Looks Like)
The best withdrawal evidence we have — the SURMOUNT-4 trial — found that people who stopped tirzepatide after 36 weeks regained much of the weight they had lost, while those who continued kept losing. That single finding reframes the whole decision: a GLP-1 is not a course of treatment you finish, it is chronic-disease management you plan for — medically and financially — before your first dose.
The trial that answered the question
For years, "what happens when I stop?" was answered with anecdote. Then SURMOUNT-4, a randomized withdrawal trial published in JAMA, answered it directly. Participants first took tirzepatide for 36 weeks; then, without knowing which group they were in, half continued the medication and half were switched to placebo.
The two groups diverged sharply. Those who continued treatment went on losing weight. Those switched to placebo regained a substantial share of what they had lost — despite the lifestyle counselling both groups received throughout. The regain was not a rare outcome among a few participants; it was the characteristic result of stopping.
This should not be surprising. Obesity is increasingly understood as a chronic condition with biological drivers — appetite signalling, energy regulation — that the medication suppresses only while it is present. Stop the medication and the biology it was counteracting comes back. Nobody calls it a failure when blood pressure rises after stopping a blood-pressure medication; the same logic applies here.
What "chronic-disease management" means in practice
The practical consequences of the SURMOUNT-4 finding are worth spelling out plainly:
- The results you may have read about assume you stay on treatment. The headline figures from trials like STEP 1 — an average loss of 14.9% of body weight over 68 weeks on semaglutide — describe people who took the medication for the full trial period. (Our breakdown of what the semaglutide trials actually show covers those numbers in detail.) The evidence does not support treating that loss as a permanent result you bank and walk away with.
- Budget for ongoing treatment before you start. If maintenance is likely to mean staying on medication indefinitely, the honest question is not "can I afford the first few months?" but "can I sustain this?" Insurance coverage for weight-loss indications remains inconsistent, so the answer often depends on what you would pay out of pocket — our guide to GLP-1 costs without insurance walks through the current landscape.
- Plan the exit before the entrance. If you already know you would stop after reaching a goal weight, discuss with a prescriber — before starting — what the evidence says about what typically follows, and what your maintenance plan would be.
The danger of the unplanned stop
Choosing to stop with a clinician's input is one thing. Having your supply disappear underneath you is another — and for many patients on compounded versions, that is exactly what has happened. The FDA has publicly detailed its concerns about unapproved compounded GLP-1 drugs, and as the regulatory environment has tightened, patients on compounded semaglutide or tirzepatide have faced abrupt interruptions when their source stopped shipping. An unplanned stop delivers the SURMOUNT-4 scenario without the planning: the medication ends, the biology returns, and there is no maintenance strategy in place.
If you are currently taking a compounded GLP-1, the supply-stability question belongs in your next clinician conversation, not in a moment of crisis. Our compounded-vs-branded explainer covers where the rules now stand.
Maintenance options to discuss with your clinician
There is no universal maintenance protocol, and we are not going to invent one. What exists is a set of approaches your prescriber can tailor to you:
Continuing at a maintenance dose
The approach most directly supported by SURMOUNT-4 is simply staying on treatment. Whether that means your current dose or a different ongoing dose is a clinical judgment your prescriber makes with you — not something to self-adjust.
Structured tapering under supervision
Some patients and clinicians attempt a gradual, supervised reduction rather than an abrupt stop, with agreed check-ins and a plan for what happens if weight returns. The evidence base here is thinner than for continued treatment, which is itself a fact worth hearing from your clinician rather than a telehealth marketing page.
Lifestyle scaffolding
Nutrition support, resistance training to preserve muscle, sleep and activity habits — these matter on or off medication, but they are scaffolding around a maintenance plan, not a proven substitute for one. In SURMOUNT-4, both groups received lifestyle counselling; it did not prevent regain in the group that stopped.
The bottom line
Start a GLP-1 with your eyes open: the evidence says stopping usually means regaining, so the decision you are really making is whether long-term treatment fits your health goals and your budget. That is a conversation for a licensed clinician — and for the fuller picture across costs, side effects and safety, see our complete GLP-1 FAQ for women.